Can a diabetes drug help fight liver cancer? early safety trial completed
NCT ID NCT02650427
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 39 times
Summary
This early study tested whether a 3-week course of sitagliptin, a diabetes drug, is safe for people with liver cancer (HCC) who are having part of their liver removed. Only 14 patients took part. The goal was to see if the drug could help the immune system attack the tumor by protecting a key immune signal. The study focused on safety and immune cell activity, not on curing the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pitié-Salpêtrière Hospital
Paris, 75013, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.